公开(公告)号：EP2717923B1

公开(公告)日：2017-09-27

申请号：EP12796547.3

申请日：2012-06-08

申请人： Ionis Pharmaceuticals, Inc.

发明人： BHATTACHARJEE, Gourab ,  REVENKO, Alexey ,  MACLEOD, Robert, A.

IPC分类号： A61K48/00 ,  C07H21/04

CPC分类号： C12N15/113 ,  A61K31/7125 ,  C12N15/1137 ,  C12N2310/11 ,  C12N2310/315 ,  C12N2310/3231 ,  C12N2310/3341 ,  C12N2310/341 ,  C12N2750/14143 ,  C12Y304/21034 ,  C12N2310/321 ,  C12N2310/3525

公开(公告)号：EP3353328A1

公开(公告)日：2018-08-01

申请号：EP16849701.4

申请日：2016-09-23

申请人： Ionis Pharmaceuticals, Inc.

发明人： REVENKO, Alexey ,  FREIER, Susan M. ,  MACLEOD, Robert A.

IPC分类号： C12Q1/68 ,  C07H21/04 ,  A61K31/7088 ,  C12N15/113

CPC分类号： C07H21/04 ,  A61K31/7088 ,  A61K31/713 ,  C12N15/113 ,  C12N2310/11 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/3231 ,  C12N2310/3341 ,  C12N2310/341 ,  C12N2310/346 ,  C12N2310/3525 ,  C12N2320/51 ,  C12Q1/68

摘要： The present embodiments provide methods, compounds, and compositions for inhibiting KRAS expression, which can be useful for treating, preventing, or ameliorating a disease associated with KRAS.

公开(公告)号：EP3823725A1

公开(公告)日：2021-05-26

申请号：EP19838248.3

申请日：2019-07-16

申请人： Aronora, Inc. ,  Oregon Health & Science University ,  Ionis Pharmaceuticals, Inc.

发明人： GRUBER, Andras ,  TUCKER, Erik ,  MONIA, Brett, P. ,  REVENKO, Alexey

IPC分类号： A61P9/10 ,  A61P9/12 ,  A61P9/14 ,  A61P11/00 ,  A61P13/12

公开(公告)号：EP3320922A1

公开(公告)日：2018-05-16

申请号：EP17192842.7

申请日：2012-06-08

申请人： Ionis Pharmaceuticals, Inc.

发明人： BHATTACHARJEE, Gourab ,  REVENKO, Alexey ,  MACLEOD, Robert A.

IPC分类号： A61K48/00 ,  C07H21/04

CPC分类号： C12N15/113 ,  A61K31/7125 ,  C12N15/1137 ,  C12N2310/11 ,  C12N2310/315 ,  C12N2310/3231 ,  C12N2310/3341 ,  C12N2310/341 ,  C12N2750/14143 ,  C12Y304/21034 ,  C12N2310/321 ,  C12N2310/3525

摘要： Disclosed herein are methods for decreasing kallikrein and treating or preventing inflammatory conditions in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to kallikrein include hereditary angioedema (HAE). Methods for inhibiting kallikrein can also be used as a prophylactic treatment to prevent individuals at risk for developing an inflammatory condition, such as, hereditary angioedema.

公开(公告)号：EP2726153B1

公开(公告)日：2018-03-28

申请号：EP12804096.1

申请日：2012-06-29

申请人： Ionis Pharmaceuticals, Inc.

发明人： REVENKO, Alexey ,  BHATTACHARJEE, Gourab ,  MACLEOD, Robert, A.

IPC分类号： C12N15/113 ,  A61K31/712 ,  A61P7/02

CPC分类号： C12N15/1137 ,  A61K31/7125 ,  A61K45/06 ,  C12N15/113 ,  C12N2310/11 ,  C12N2310/315 ,  C12N2310/322 ,  C12N2310/3231 ,  C12N2310/341 ,  C12N2310/345 ,  C12N2310/3525

摘要： Disclosed herein are methods for decreasing kallikrein and treating or preventing thromboembolic conditions in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to kallikrein include thrombosis, embolism, and thromboembolism, such as, deep vein thrombosis, pulmonary embolism, myocardial infarction, and stroke. Methods for inhibiting kallikrein can also be used as a prophylactic treatment to prevent individuals at risk for thrombosis and embolism.

公开(公告)号：EP4363563A1

公开(公告)日：2024-05-08

申请号：EP22834228.3

申请日：2022-06-30

申请人： Ionis Pharmaceuticals, Inc.

发明人： CROSBY, Jeffrey, R. ,  ZHAO, Chenguang ,  REVENKO, Alexey ,  GUO, Shuling

IPC分类号： C12N9/02 ,  C12N15/113 ,  A61K31/00 ,  A61P11/00

CPC分类号： A61P11/00 ,  C12N9/0036 ,  C12Y106/03001 ,  C12N2310/34120130101 ,  C12N2310/323120130101 ,  C12N2310/1120130101 ,  C12N15/1137 ,  C12N2310/31520130101 ,  C12N2310/34320130101 ,  A61K31/713 ,  A61K31/7088

公开(公告)号：EP3880211A1

公开(公告)日：2021-09-22

申请号：EP19885706.2

申请日：2019-11-14

申请人： Ionis Pharmaceuticals, Inc.

发明人： REVENKO, Alexey ,  MACLEOD, Robert, A. ,  FREIER, Susan, M.

IPC分类号： A61K31/712 ,  A61K31/7125 ,  C07H21/02 ,  C12N15/11 ,  C12N15/113